Sunday, October 15, 2017 12:33:42 PM
Janssen, nor anyone else-wrong
There have been no collaborative agreements with Jannsen (or anyone else) announced.
CIAB has not shown any superiority to any pancreatic cancer treatment currently undergoing FDA trials. There have been no approved FDA clinical trials with CIAB. There's no FDA trial data generated by CIAB. Where's the IND?
Neither have there been any clinical studies with an alkylating agent such as Ifosfamide, having been used alone as a Metronomic therapy for metastatic Pancreatic cancer. That is why a Jansen and "anyone else" isn't interested.
for that matter would be interested in PharmaCyte's CiaB therapy if that was true.
There have been no collaborative agreements with Jannsen (or anyone else) announced.
You can't show not one single targeted therapy having superior intellectual property to CiaB
CIAB has not shown any superiority to any pancreatic cancer treatment currently undergoing FDA trials. There have been no approved FDA clinical trials with CIAB. There's no FDA trial data generated by CIAB. Where's the IND?
Neither have there been any clinical studies with an alkylating agent such as Ifosfamide, having been used alone as a Metronomic therapy for metastatic Pancreatic cancer. That is why a Jansen and "anyone else" isn't interested.
The Jewel of the Mind is Colored with the Hue of what it Imagines
Recent PMCB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:16:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:19:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/17/2026 07:49:54 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/09/2026 01:40:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 10:02:46 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 10:05:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/18/2025 10:04:23 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 12/15/2025 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2025 10:07:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 10:00:25 PM
- PharmaCyte Biotech stock surges following profitable exit from Femasys investment • IH Market News • 11/25/2025 03:56:47 PM
- PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment • Business Wire • 11/25/2025 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:32:29 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/18/2025 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/06/2025 09:08:43 PM
